Literature DB >> 21970614

Strategy and its implications of protein bioanalysis utilizing high-resolution mass spectrometric detection of intact protein.

Qian Ruan1, Qin C Ji, Mark E Arnold, W Griffith Humphreys, Mingshe Zhu.   

Abstract

Currently, mass spectrometry-based protein bioanalysis is primarily achieved through monitoring the representative peptide(s) resulting from analyte protein digestion. However, this approach is often incapable of differentiating the measurement of protein analyte from its post-translational modifications (PTMs) and/or potential biotransformation (BTX) products. This disadvantage can be overcome by direct measurement of the intact protein analytes. Selected reaction monitoring (SRM) on triple quadrupole mass spectrometers has been used for the direct measurement of intact protein. However, the fragmentation efficiency though the SRM process could be limited in many cases, especially for high molecular weight proteins. In this study, we present a new strategy of intact protein bioanalysis by high-resolution (HR) full scan mass spectrometry using human lysozyme as a model protein. An HR linear ion-trap/Orbitrap mass spectrometer was used for detection. A composite of isotopic peaks from one or multiple charge states can be isolated from the background and used to improve the signal-to-noise ratio. The acquired data were processed by summing extracted ion chromatograms (EIC) of the 10 most intense isotopic ions of octuply protonated lysozyme. Quantitation of the plasma lysozyme was conducted by utilizing high resolving power and an EIC window fitting to the protein molecular weight. An assay with a linear dynamic range from 0.5 to 500 μg/mL was developed with good accuracy and precision. The assay was successfully employed for monitoring the level of endogenous lysozyme and a potential PTM in human plasma. The current instrumentation limitations and potential advantages of this approach for the bioanalysis of large proteins are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21970614     DOI: 10.1021/ac201540t

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  6 in total

1.  Optimizing High-Resolution Mass Spectrometry for the Identification of Low-Abundance Post-Translational Modifications of Intact Proteins.

Authors:  Lisa E Kilpatrick; Eric L Kilpatrick
Journal:  J Proteome Res       Date:  2017-08-08       Impact factor: 4.466

2.  LC-MS Differential Analysis for Fast and Sensitive Determination of Biotransformation of Therapeutic Proteins.

Authors:  Ming Yao; Bingming Chen; Weiping Zhao; John T Mehl; Lingjun Li; Mingshe Zhu
Journal:  Drug Metab Dispos       Date:  2018-01-31       Impact factor: 3.922

3.  Intact quantitative bioanalytical method development and fit-for-purpose validation of a monoclonal antibody and its related fab fragment in human vitreous and aqueous humor using LC-HRMS.

Authors:  Catherine E DelGuidice; Omnia A Ismaiel; William R Mylott; Moucun Yuan; Matthew S Halquist
Journal:  Anal Bioanal Chem       Date:  2022-04-22       Impact factor: 4.142

Review 4.  Deciphering post-translational modification codes.

Authors:  Adam P Lothrop; Matthew P Torres; Stephen M Fuchs
Journal:  FEBS Lett       Date:  2013-02-10       Impact factor: 4.124

5.  Characterization and quantification of intact 26S proteasome proteins by real-time measurement of intrinsic fluorescence prior to top-down mass spectrometry.

Authors:  Jason D Russell; Mark Scalf; Adam J Book; Daniel T Ladror; Richard D Vierstra; Lloyd M Smith; Joshua J Coon
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

6.  Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry.

Authors:  John F Kellie; Richard E Higgs; John W Ryder; Anthony Major; Thomas G Beach; Charles H Adler; Kalpana Merchant; Michael D Knierman
Journal:  Sci Rep       Date:  2014-07-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.